Difficult-to-treat Takayasu arteritis: a case-based review.
Biological therapy
Janus kinase inhibitors
Management
Takayasu arteritis
Tocilizumab
Tumor necrosis factor inhibitors
Journal
Rheumatology international
ISSN: 1437-160X
Titre abrégé: Rheumatol Int
Pays: Germany
ID NLM: 8206885
Informations de publication
Date de publication:
23 Oct 2024
23 Oct 2024
Historique:
received:
02
07
2024
accepted:
14
10
2024
medline:
23
10
2024
pubmed:
23
10
2024
entrez:
23
10
2024
Statut:
aheadofprint
Résumé
Takayasu arteritis is a rare chronic inflammatory large vessel vasculitis which affects the aorta and its large branches. The diagnosis is based on the 2022 ACR/EULAR classification criteria for Takayasu arteritis. The management of this vasculitis is challenging. Although it is corticosteroid-responsive, relapses and disease progression are common. Thus, it is possible to resort to alternative conventional synthetic disease-modifying anti-rheumatic drugs and biologics, as second-line such as tumor necrosis factor-alpha inhibitors, tocilizumab, or JAK inhibitors as second-line agents is possible. Nevertheless, in some complex cases, the vasculitis remains active despite different proposed therapeutic lines, and a multitarget approach could induce sustained remission. We report herewith a case of 33-female patient with a refractory Takayasu arteritis which remained active after three different therapeutic lines with tocilizumab, then infliximab, then Upadacitinib. Finally, we consider a successful multitarget approach with a combination of infliximab, Upadacitinib, and methotrexate.
Identifiants
pubmed: 39441396
doi: 10.1007/s00296-024-05741-y
pii: 10.1007/s00296-024-05741-y
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Jennette JC, Falk RJ, Bacon PA, Basu N, Cid MC, Ferrario F et al (2013) 2012 revised international chapel Hill Consensus Conference nomenclature of Vasculitides. Arthritis Rheum 65:1–11
Onen F, Akkoc N (2017) Epidemiology of Takayasu arteritis. Presse Medicale Paris Fr 1983 46:e197–203
Tomelleri A, Padoan R, Kavadichanda CG, Jose A, Singh K, Iorio L et al (2023) Validation of the 2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis. Rheumatol Oxf Engl 62:3427–3432
doi: 10.1093/rheumatology/kead161
Monti S, Águeda AF, Luqmani RA, Buttgereit F, Cid M, Dejaco C et al (2019) Systematic literature review informing the 2018 update of the EULAR recommendation for the management of large vessel vasculitis: focus on giant cell arteritis. RMD Open 5:e001003
doi: 10.1136/rmdopen-2019-001003
pubmed: 31673411
pmcid: 6803016
Nakaoka Y, Isobe M, Takei S, Tanaka Y, Ishii T, Yokota S et al (2018) Efficacy and safety of tocilizumab in patients with refractory Takayasu arteritis: results from a randomised, double-blind, placebo-controlled, phase 3 trial in Japan (the TAKT study). Ann Rheum Dis 77:348–354
doi: 10.1136/annrheumdis-2017-211878
pubmed: 29191819
Sun X, Fang C, Jin S, Li J, Yang Y, Zeng X et al (2024) Serum IL-6 level trajectory for predicting the effectiveness and safety of tocilizumab in the treatment of refractory Takayasu arteritis. Eur J Intern Med 126:77–82
doi: 10.1016/j.ejim.2024.04.004
pubmed: 38643043
Tian X, Zeng X (2024) Chinese guideline for the diagnosis and treatment of Takayasu’s arteritis (2023). Rheumatol Immunol Res 5:5–26
doi: 10.1515/rir-2024-0002
pubmed: 38571931
pmcid: 10985707
Grayson PC, Ponte C, Suppiah R, Robson JC, Gribbons KB, Judge A et al (2022) 2022 American College of Rheumatology/EULAR classification criteria for Takayasu arteritis. Ann Rheum Dis 81:1654–1660
doi: 10.1136/ard-2022-223482
pubmed: 36351705
MV P, Maikap D, Padhan P (2023) Successful use of Tofacitinib in Refractory Takayasu Arteritis: a Case Series. Mediterr J Rheumatol 34:356–362
doi: 10.31138/mjr.230929.su
pubmed: 37941853
pmcid: 10628870
Zhou Z, Fang C, Wang L, Li J, Yang Y, Zhang L et al (2024) Baricitinib for refractory Takayasu arteritis: a prospective cohort study in a tertiary referral centre. RMD Open 10:e003985
doi: 10.1136/rmdopen-2023-003985
pubmed: 38519108
pmcid: 10961550
As C, Danda D (2023) Current diagnosis and management of Takayasu Arteritis. Int Heart J 64:519–534
doi: 10.1536/ihj.23-195
pubmed: 37518335
Bhandari S, Butt SRR, Ishfaq A, Attaallah MH, Ekhator C, Halappa Nagaraj R et al (2023) Pathophysiology, diagnosis, and management of Takayasu Arteritis: a review of current advances. Cureus 2915:e42667
Arita Y, Ishibashi T, Nakaoka Y (2023) Current immunosuppressive treatment for Takayasu Arteritis. Circ J off J Jpn Circ Soc 88(10)
Moisii P, Jari I, Naum AG, Butcovan D, Tinica G (2024) Takayasu’s arteritis: a Special Case Report and Review of the literature. Med (Mex 60:456
Łoń I, Leśnowolski Ł, Janiec I, Januszewicz M, Sobieraj P, Lewandowski J (2024) Severe course of type IV Takayasu disease during treatment with etanercept. Pol Arch Intern Med 134:16606
pubmed: 37965981
Mekinian A, Biard L, Lorenzo D, Novikov PI, Salvarani C, Espitia O et al (2023) Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study. RMD Open 9:e002830
doi: 10.1136/rmdopen-2022-002830
pubmed: 37321669
pmcid: 10277523
Mekinian A, Saadoun D, Vicaut E, Thietart S, Lioger B, Jego P et al (2020) Tocilizumab in treatment-naïve patients with Takayasu arteritis: TOCITAKA French prospective multicenter open-labeled trial. Arthritis Res Ther 22:218
doi: 10.1186/s13075-020-02311-y
pubmed: 32943098
pmcid: 7500024
Hellmich B, Agueda A, Monti S, Buttgereit F, de Boysson H, Brouwer E et al (2020) 2018 update of the EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis 79:19–30
doi: 10.1136/annrheumdis-2019-215672
pubmed: 31270110
Peron Filho F, Moreira A, de Janes S, de Souza ALF (2024) Effectiveness and safety of adalimumab compared with leflunomide in patients with Takayasu arteritis: a retrospective cohort study. RMD Open 10:e003992
doi: 10.1136/rmdopen-2023-003992
pubmed: 38443091
pmcid: 11146362
Mekinian A, Biard L, Dagna L, Novikov P, Salvarani C, Espitia O et al (2022) Efficacy and safety of TNF-α antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients. Rheumatol Oxf Engl 61:1376–1384
doi: 10.1093/rheumatology/keab635
Valsakumar AK, Valappil UC, Jorapur V, Garg N, Nityanand S, Sinha N (2003) Role of immunosuppressive therapy on clinical, immunological, and angiographic outcome in active Takayasu’s arteritis. J Rheumatol 30:1793–1798
pubmed: 12913937
Baert F, De Vos M, Louis E, Vermeire S, Belgian IBD, Research Group (2007) Immunogenicity of infliximab: how to handle the problem? Acta Gastro-Enterol. Belg 70:163–170
Kaymakci MS, Warrington KJ, Kermani TA (2024) New therapeutic approaches to large-vessel vasculitis. Annu Rev Med 75:427–442
doi: 10.1146/annurev-med-060622-100940
pubmed: 37683286
Dimitroulas T (2023) Tofacitinib as a promising therapeutic option in refractory autoimmune-mediated vascular and sclera inflammation. Mediterr J Rheumatol 34:282–283
doi: 10.31138/mjr.20230929.taa
pubmed: 37941867
pmcid: 10628872
Kong X, Sun Y, Dai X, Wang L, Ji Z, Chen H et al (2022) Treatment efficacy and safety of tofacitinib versus methotrexate in Takayasu arteritis: a prospective observational study. Ann Rheum Dis 81:117–123
doi: 10.1136/annrheumdis-2021-220832
pubmed: 34362744
Wang J, Dai X, Ma L, Wu S, Jin X, Ji Z et al (2022) Efficacy and safety of tofacitinib versus leflunomide with glucocorticoids treatment in Takayasu arteritis: a prospective study. Semin Arthritis Rheum 55:152018
doi: 10.1016/j.semarthrit.2022.152018
pubmed: 35523066
Mekinian A, Noé L, Salvarani C, Dagna L, Espitia O, Biard L et al (2024) Effectiveness and safety of Rituximab in Takayasu arteritis: a multicenter retrospective study. Joint Bone Spine 91:105658
doi: 10.1016/j.jbspin.2023.105658
pubmed: 37913918
Caltran E, Di Colo G, Ghigliotti G, Capecchi R, Catarsi E, Puxeddu I et al (2014) Two Takayasu arteritis patients successfully treated with rituximab. Clin Rheumatol 33:1183–1184
doi: 10.1007/s10067-014-2506-5
pubmed: 24478126
Ernst D, Greer M, Stoll M, Meyer-Olson D, Schmidt RE, Witte T (2012) Remission achieved in Refractory Advanced Takayasu Arteritis using Rituximab. Case Rep. Rheumatol 2012:406963
Saur SJ, Horger M, Henes J (2021) Successful treatment with the IL12/IL23 antagonist ustekinumab in a patient with refractory Takayasu arteritis. Rheumatol Adv Pract 5:rkaa082
doi: 10.1093/rap/rkaa082
pubmed: 33604503
pmcid: 7878844
Gon Y, Yoshifuji H, Nakajima T, Murakami K, Nakashima R, Ohmura K et al (2021) Long-term outcomes of refractory Takayasu arteritis patients treated with biologics including ustekinumab. Mod Rheumatol 31:678–683
doi: 10.1080/14397595.2020.1800560
pubmed: 32700985